Results 21 to 30 of about 332,330 (302)

Ocular graft-versus-host disease: An update on immune pathogenesis and therapies

Medicina Universitaria, 2022
Hematopoietic stem cell transplantation (HSCT) is a treatment option for hematological and non-hematological diseases that do not respond to conventional treatments.
Samantha P. Peña-Lozano, Luz M. Barbosa-Castillo, Adriana E. Partida-García, Perla R. Colunga-Pedraza   +3 more
doaj   +1 more source

Breakdown of thymic tolerance - an etiologic link between acute and chronic graft-versus-host disease [PDF]

, 2014
Allogeneic haematopoietic stem cell transplantation (HSCT) is the standard therapy for many disorders of the haematological system. Its use is limited by the major complication acute graft-versus-host disease (GVHD). Development of acute GVHD predisposes
Dertschnig, Simone
core   +1 more source

Cytokines in Graft-versus-Host Disease [PDF]

The Journal of Immunology, 2015
Abstract Graft-versus-host disease (GVHD) is a complication of allogeneic bone marrow transplantation whereby transplanted naive and marrow-derived T cells damage recipient tissue through similar mechanisms to those that allow destruction of malignant cells, the therapeutic intent of bone marrow transplantation.
Henden, Andrea S., Hill, Geoffrey R.
openaire   +5 more sources

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated

Haematologica, 2018
Upper gastrointestinal acute graft-versus-host disease is reported in approximately 30% of hematopoietic stem cell transplant recipients developing acute graft-versus-host disease.
Sarah Nikiforow, Tao Wang, Michael Hemmer, Stephen Spellman, Görgün Akpek, Joseph H. Antin, Sung Won Choi, Yoshihiro Inamoto, Hanna J. Khoury, Margaret MacMillan, David I. Marks, Ken Meehan, Hideki Nakasone, Taiga Nishihori, Richard Olsson, Sophie Paczesny, Donna Przepiorka, Vijay Reddy, Ran Reshef, Hélène Schoemans, Ned Waller, Daniel Weisdorf, Baldeep Wirk, Mary Horowitz, Amin Alousi, Daniel Couriel, Joseph Pidala, Mukta Arora, Corey Cutler   +28 more
doaj   +1 more source

The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality

Haematologica, 2011
Background The 2005 National Institutes of Health Consensus Development Conference on chronic graft-versus-host disease proposed major changes in the classification and grading of severity of chronic graft-versus-host disease.Design and Methods We aimed ...
Joseph Pidala, Jongphil Kim, Claudio Anasetti, Taiga Nishihori, Brian Betts, Teresa Field, Janelle Perkins   +6 more
doaj   +1 more source

When donor T cells attack: The curious case of liver transplant-associated acute graft-versus-host-disease

Science Progress, 2022
Graft versus host disease is a rare but deadly complication of solid organ transplant. Clinical features of graft-versus-host-disease are non-specific, which may lead to delayed diagnosis as more common conditions including infections or drug reactions ...
Max Deschner, Donald J. Bastin, Ziad Solh, Karen Bosma, Wael Haddara, Ping Yang, Robert Broadbent, Aaron Haig, Jonathan Keow, Mayur Brahmania, Anargyros Xenocostas, Uday Deotare   +11 more
doaj   +1 more source

Vitiligo: an uncommon cutaneous manifestation of graft versus host disease

Pigment International, 2022
Graft versus host disease (GVHD) is the most serious complication of hematopoietic stem cell transplantation. Skin is the most commonly affected organ, in both acute and chronic GVHD with a variable clinical spectrum of presentation with the typical skin
Preema Sinha, Anwita Sinha, Subramaniyan Radhakrishnan, Jasvinder Kaur Bhatia   +3 more
doaj   +1 more source

Beta herpes viruses in patients with cutaneous graft-versus-host disease

Журнал инфектологии, 2015
Graft-versus-host disease is a major complication of allogenic bone marrow transplantation. Beta herpes viruses’ role in pathogenesis and prognosis of graft-versus-host disease is significant.
V. V. Baykov, I. S. Moiseev, A. Yu. Petrova, E. V. Lisukova, I. E. Belousova, I. O. Smirnova, I. N. Telichko   +6 more
doaj   +1 more source

Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults

Haematologica, 2016
We previously reported that bone marrow grafts from matched sibling donors resulted in best graft-versus-host disease-free, relapse-free survival at 1-year post allogeneic hematopoietic cell transplantation.
Rohtesh S. Mehta, Regis Peffault de Latour, Todd E DeFor, Marie Robin, Aleksandr Lazaryan, Aliénor Xhaard, Nelli Bejanyan, Flore Sicre de Fontbrune, Mukta Arora, Claudio G. Brunstein, Bruce R. Blazar, Daniel J. Weisdorf, Margaret L. MacMillan, Gerard Socie, Shernan G. Holtan   +14 more
doaj   +1 more source

Adoptive Immunotherapy in Chimeras with Donor Lymphocytes [PDF]

, 2003
Allogeneic stem cell transplantation has a well-defined indication in the treatment of hematological malignancies. The beneficial immune effect of allogeneic marrow transplantation has long been known, but only recently have methods been developed to ...
Kolb, Hans-Jochem, Roskrow, Marie, Guenther, Wolfgang, Schmid, Christoph, Ledderose, Georg, Weber, Martin, Chen, Xiao, Schleuning, Michael, Woiciechowski, Anja   +8 more
core   +1 more source